Isto’s Chief Commercial Officer Presents at the 2017 Canaccord Genuity Musculoskeletal Conference
Mar 27, 2017
Phil Kuhn, Isto Biologics’ Chief Commercial Officer, presented at the annual Canaccord Genuity Musculoskeletal Conference where he shared recent milestones for Isto and plans for projected growth.
Mr. Kuhn was among industry leaders who gathered at Canaccord on Tuesday, March 14 in San Diego, CA to present company updates and commentary on the orthopedic medical device and biologics market landscapes. He presented on Isto Biologics’ best-in-class product portfolio and shared that Isto’s forward-looking performance will be driven by a combination of organic growth along with acquisitions and licensing. Kuhn also discussed how Isto Biologics is differentiated in the space through its unique offering of biologic products and services, backed by science and deep clinical expertise.
“It is an honor to be invited to present alongside other orthopedic industry leaders, and a great opportunity to share what is happening at Isto Biologics,” stated Mr. Kuhn.
Canaccord Genuity Group Inc. is a global, full-service investment banking and financial services company that specializes in wealth management and brokerage in capital markets. Their 12th Annual Musculoskeletal Conference featured over 50 company presentations to explore the current state of the musculoskeletal market – including orthopedics, robotic and computer-assisted surgery, regenerative tissue, wound care, and imaging markets.
Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, integrated under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.